DB-289, an oral diamidoxime prodrug of DB-75 from the University of North Carolina, Georgia State University, Auburn University and Duke University, is being developed by Immtech International as a potential treatment for Pneumocystis carinii pneumonia (PCP), tuberculosis, trypanosomiasis and malaria.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
immtech international
8
db-289 immtech
4
international db-289
4
db-289 oral
4
oral diamidoxime
4
diamidoxime prodrug
4
prodrug db-75
4
university
4
db-75 university
4
university north
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!